Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.50 |
| ▸ | KMO | O15229 | 2/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 15/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23308729 | 1.00 | KDM4E (0.54) | KDM4EGLAHTTKMT2ASMN1; SMN2 | |
| SCHEMBL10586417 | 0.84 | KDM4E (0.54) | KDM4EGLAHTTKMT2ASMN1; SMN2 | |
| SCHEMBL25690401 | 0.76 | EGLN1 (0.48) | EGLN1 | |
| SCHEMBL25690381 | 0.76 | EGLN1 (0.48) | EGLN1 | |
| SCHEMBL25690358 | 0.76 | EGLN1 (0.46) | EGLN1 | |
| SCHEMBL20400868 | 0.75 | KDM4E (0.64) | KDM4EGLAHTTKMT2ASMN1; SMN2 | |
| SCHEMBL28162728 | 0.73 | SMURF2 (0.46) | KDM4EGLAHTTKMT2ASMN1; SMN2 | |
| SCHEMBL19759808 | 0.73 | KDM4E (0.45) | KDM4EGLAHTTKMT2ASMN1; SMN2 | |
| SCHEMBL1584463 | 0.73 | KDM4E (0.41) | KDM4EGLAHTTKMT2ASMN1; SMN2 | |
| SCHEMBL11777644 | 0.70 | ACMSD (0.66) | KDM4EGLAHTTKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738010-B2 | Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides | AKEBIA THERAPEUTICS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738010-B2 | Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides | HPD, APEH, P4HA1 | KDM4E 779/4885GLA 847/4885HTT 1486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.